When was Plexium founded?

Plexium was founded in 2017 and raised its 1st funding round 1 year after it was founded.

Where is Plexium located?

Plexium is headquartered in San Diego, United States. It is registered at San Diego, California.

How many employees does Plexium have?

As of May 31, 2026, the latest employee count at Plexium is 36.

Is Plexium a funded company?

Plexium is a funded company, having raised a total of $225M across 5 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Feb 2018.

When was the latest funding round of Plexium?

Plexium's latest funding was a $***** Series B round on Jul 14, 2025, with participation from 0 investor.

Where does Plexium rank among its competitors?

Plexium ranks 109th amongst 2425 active competitors, of which 843 are funded. It stands 4th in terms of total funding among its competitors. The most recent competitor to raise funding was Karyopharm, which secured $30M in Mar, 2026.

Who are the top competitors of Plexium?

Plexium's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Blueprint Medicines. Among them, Karyopharm secured the most recent funding round in March, 2026.

Plexium - 2026 Company Profile, Team, Funding & Competitors

Plexium is a series B company based in San Diego (United States), founded in 2017 by Andrew MacConnell and Joe Rokicki. It operates as a Precision medicine company pioneering targeted protein degradation therapeutics. Plexium has raised $225M in funding from investors like DCVC, Lux Capital and The Column Group. The company has 2425 active competitors, including 843 funded and 599 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Blueprint Medicines.

Company Details

Precision medicine company pioneering targeted protein degradation therapeutics. This is a next-generation targeted protein degradation (TPD) company focused on rationally designing and discovering Monovalent Direct Degraders and Molecular Glues. Through its comprehensive best-in-class TPD platform powered by a proprietary ultra-high throughput cell-based screening (uHTS) technology, it is pushing the boundaries of TPD. The company is committed to delivering life-changing medicines to patients through a differentiated platform of proprietary technologies and approaches to establish a robust and diverse portfolio of monovalent targeted protein degrader therapeutics. The company is focused on rational design and discovery, and is developing therapeutics for patients in need.

Website: plexium.com
Social
Registered Address: San Diego, California

Key Metrics

Founded Year

2017

Location

San Diego, United States

Stage

Series B

Total Funding

$225M in 5 rounds

Latest Funding Round

Series B, Jul 14, 2025, $*****

Investors

DCVC & 15 more

Ranked

109^th among 2425 active competitors

Employee Count

36 as on May 31, 2026

Similar Companies

Amphista Therapeutics & 24 more

View Plexium's full profile

Plexium is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Plexium, Inc. CIN: 822230262 , United States, Active	Dec 31, 1999	-	68 (As on Dec 31, 2024)	-

Plexium has raised a total funding of $225M over 5 rounds. Its first funding round was on Feb 2018. Plexium has 16 institutional investors.

Here is the list of recent funding rounds of Plexium:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 14, 2025	2659457	Series B	4677584	9517183	6761224	2294390
Feb 23, 2022	3964987	Series B	4390045	4504863	9741674	RA Capital Management & 10 more
Jan 21, 2021	3621229	Series A	8519467	9450109	Lux Capital & 1 more	The Column Group & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of Plexium's funding rounds and investors

The founders of Plexium are Andrew MacConnell and Joe Rokicki.

Here are the details of Plexium's key team members:

Andrew MacConnell: Co-Founder of Plexium.
Joe Rokicki: Co-Founder of Plexium.
Kandaswamy Vijayan: CEO of Plexium.
Contact Info: 1 email address

View details of Plexium's Founder profiles and Board Members

Plexium's employee count trend

Plexium has 36 employees as of May 26. Here is Plexium's employee count trend over the years:

Uncover Plexium's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Plexium include Jazz Pharmaceuticals, Sana Biotechnology and Blueprint Medicines. Here is the list of Top 10 competitors of Plexium, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating human disease conditions	$821M	Baillie Gifford, Bezos Expeditions & 17 others	75/100
3rd	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Nextech Invest, Third Rock Ventures & 20 others	72/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	Boxer Capital, BVF Partners & 15 others	72/100
5th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Karyopharm 2008, Natick (United States), Public	Developer of small molecule drugs for the treatment of cancer and inflammatory disease	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Zymeworks 2003, Vancouver (Canada), Public	Developer of bi-specific antibodies & antibody-drug conjugates to treat cancer	$146M	CTI Life Sciences Fund, Advanced Biotechnologies Venture Fund ... & 16 others	71/100
109th	Plexium 2017, San Diego (United States), Series B	Precision medicine company pioneering targeted protein degradation therapeutics	$225M	BVF Partners, RA Capital Management & 14 others	61/100